Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CPN1 | P15169 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630538 | 0.85 | ALDH1A1 (0.34) | PDE4BALDH1A1MAPK1LMNAGLA | |
| SCHEMBL2639869 | 0.78 | ALDH1A1 (0.38) | ALDH1A1MAPK1LMNA | |
| SCHEMBL4755082 | 0.77 | GAA (0.31) | PDE4B | |
| SCHEMBL15808574 | 0.76 | CA12 (0.48) | PDE4BALDH1A1 | |
| SCHEMBL14311858 | 0.76 | CA12 (0.48) | PDE4BALDH1A1 | |
| SCHEMBL15808643 | 0.76 | CA12 (0.48) | PDE4BALDH1A1 | |
| SCHEMBL4757546 | 0.75 | ALDH1A1 (0.41) | ALDH1A1LMNAHPGD | |
| SCHEMBL29980508 | 0.74 | ALDH1A1 (0.56) | ALDH1A1LMNAHSD17B10HPGD | |
| SCHEMBL19176270 | 0.74 | PDE4B (0.35) | PDE4BALDH1A1MAPK1LMNAGLA | |
| SCHEMBL4757299 | 0.74 | CHRNB2 (0.40) | PDE4BALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | PDE4B 1291/4885ALDH1A1 3412/4885MAPK1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.